SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Chardan Capital maintains Buy on Palvella Therapeutics; $240 target

Benzinga reports Chardan Capital maintained a Buy rating on Palvella Therapeutics and kept its $240.00/share price target.

PVLA

Related stories